1. Home
  2. BLIN vs SKYE Comparison

BLIN vs SKYE Comparison

Compare BLIN & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bridgeline Digital Inc.

BLIN

Bridgeline Digital Inc.

HOLD

Current Price

$0.71

Market Cap

9.0M

Sector

Technology

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$1.52

Market Cap

7.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLIN
SKYE
Founded
2000
2012
Country
United States
United States
Employees
40
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.0M
7.4M
IPO Year
2018
2013

Fundamental Metrics

Financial Performance
Metric
BLIN
SKYE
Price
$0.71
$1.52
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $68.00
AVG Volume (30 Days)
★ 59.8K
26.4K
Earning Date
08-13-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $13,568,000.00
N/A
Revenue This Year
$20.26
N/A
Revenue Next Year
$21.08
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.66
$0.26
52 Week High
$1.42
$13.12

Technical Indicators

Market Signals
Indicator
BLIN
SKYE
Relative Strength Index (RSI) 35.28 41.50
Support Level $0.69 $1.52
Resistance Level $1.05 $2.28
Average True Range (ATR) 0.07 0.10
MACD 0.00 0.02
Stochastic Oscillator 18.30 18.52

Price Performance

Historical Comparison
BLIN
SKYE

About BLIN Bridgeline Digital Inc.

Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: